Modern approaches to the treatment of inflammatory bowel disease in children according to the latest recommendations of the European Organization for the Study of Crohn's disease and colitis, and the European Society of Pediatric Gastroenterologists, Hepa

Authors

  • O.M. Okhotnikova Kyiv Children's Specialized Clinic «OHMADYT», Kyiv, Ukraine, Ukraine
  • T.M. Tkacheva Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0001-8951-7767
  • A.A. Romanchuk Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine
  • O.M. Grishchenko Kyiv Children's Specialized Clinic «OHMADYT», Kyiv, Ukraine, Ukraine
  • L.V. Semenenko Kyiv Children's Specialized Clinic «OHMADYT», Kyiv, Ukraine, Ukraine

DOI:

https://doi.org/10.15574/SP.2021.114.40

Keywords:

ulcerative colitis, recommendations, children, anti-TNF, calprotectin, unclassified inflammatory bowel disease, monitoring, activity index, treatment

Abstract

Modern outpatient management of ulcerative colitis (UC) continues to be a difficult task, as 20% of children still need colectomy (there are no official statistics for Ukraine). Therefore, the European Organization for the Study of Crohn's Disease and Colitis (ECCO) and the European Society of Pediatric Gastroenterologists, Hepatologists and Nutritionists (ESPGHAN), seeking to standardize the daily treatment of inflammatory bowel disease (IBD), have developed a protocol for the management and treatment of children with VC. Based on the analysis of medical research, followed by an evidentiary assessment of each provision, the 2012 recommendations were updated.

The aim is to present the provisions of the updated protocol on therapeutic management of children with ulcerative colitis and to consolidate the material on a clinical case.

Materials and methods. The article presents updated recommendations of ECCO and ESPGHAN (2018) on the treatment of COPD in children, the algorithm of induction and maintenance of remission of UC and COPD unclassified. A clinical case is given for an example of application of the algorithm of induction and support of remission of IBD at children, assessment of severity and the scheme of management of patients with this pathology is provided.

Results and conclusions. The updated recommendations of ECCO and ESPGHAN facilitate the treatment of unclassified UC and IBD, provide a clear scheme for monitoring children with this pathology, which improves treatment outcomes and quality of life of young patients.

The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies.

No conflict of interest was declared by the authors.

References

Abdelrazeq AS, Kandiyil N, Botterill ID et al. (2008). Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 10: 805-813. https://doi.org/10.1111/j.1463-1318.2007.01413.x; PMid:18005192

Alexandre B, Vandermeeren Y, Dewit O et al. (2016). Optic neuritis associated or not with TNF antagonists in patients with inflammatory bowel disease. J Crohns Colitis. 10: 541-548. https://doi.org/10.1093/ecco-jcc/jjw003; PMid:26759360 PMCid:PMC4957451

Barabino A, Torrente F, Ventura A et al. (2002). Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment Pharmacol Ther. 16: 1125-1130. https://doi.org/10.1046/j.1365-2036.2002.01269.x; PMid:12030954

Baud O, Goulet O, Canioni D et al. (2001). Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med. 344: 1758-1762. https://doi.org/10.1056/NEJM200106073442304; PMid:11396442

Beattie RM, Nicholls SW, Domizio P et al. (1996). Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr. 22: 373-379. https://doi.org/10.1097/00005176-199605000-00006; PMid:8732900

Begue B, Verdier J, Rieux Laucat F et al. (2011). Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol. 106: 1544-1555. https://doi.org/10.1038/ajg.2011.112; PMid:21519361

Benchimol EI, Mack DR, Nguyen GC et al. (2014). Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology. 147: 803-813. https://doi.org/10.1053/j.gastro.2014.06.023; PMid:24951840

Bigorgne AE, Farin HF, Lemoine R et al. (2013). TTC7A mutations disrupt intestinal epithelial apicobasal polarity. J Clin Invest. 124: 328-337. https://doi.org/10.1172/JCI71471; PMid:24292712 PMCid:PMC3871247

Cakir M, Ozgenc F, Yusekkaya HA et al. (2011). Steroid response in moderate to severe pediatric ulcerative colitis: a single center's experience. World J Pediatr. 7: 50-53. https://doi.org/10.1007/s12519-011-0245-0; PMid:21191776

Carter MJ, Di Giovine FS, Cox A et al. (2001). The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology. 121: 805-811. https://doi.org/10.1053/gast.2001.28017; PMid:11606494

Cohen RD, Dalal SR. (2015). Systematic review: rectal therapies for the treatment of distal forms of ulcerative colitis. Inflamm Bowel Dis. 21: 1719-1736. https://doi.org/10.1097/MIB.0000000000000379; PMid:26020604

Connell WR, Kamm MA, Ritchie JK et al. (1993). Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 34: 1081-1085. https://doi.org/10.1136/gut.34.8.1081; PMid:8174958 PMCid:PMC1374358

Connolly MP, Poole CD, Currie CJ et al. (2009). Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. Digestion. 80: 241-246. https://doi.org/10.1159/000235916; PMid:19828955

Damen GM, van Krieken JH, Hoppenreijs E et al. (2010). Overlap, common features, and essential differences in pediatric granulomatous inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 51: 690-697. https://doi.org/10.1097/MPG.0b013e3181dc0d73; PMid:20683205

Dharmaraj R, Dasgupta M, Simpson P et al. (2016). Predictors of pouchitis after ileal pouch-anal anastomosis in children. J Pediatr Gastroenterol Nutr. 63: e58-62. https://doi.org/10.1097/MPG.0000000000001279; PMid:27243421

Dhillon SS, Fattouh R, Elkadri A et al. (2014). Variants in nicotinamide adenine dinucleotide phosphate oxidase complex components determine susceptibility to very early onset inflammatory bowel disease. Gastroenterology. 147: 680-689. https://doi.org/10.1053/j.gastro.2014.06.005; PMid:24931457

Dignass A, Eliakim R, Magro F et al. (2012). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 6: 965-990. https://doi.org/10.1016/j.crohns.2012.09.003; PMid:23040452

Dotson JL, Hyams JS, Markowitz J et al. (2010). Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr. 51: 140-145. https://doi.org/10.1097/MPG.0b013e3181ca4db4; PMid:20453677

Fabre A, Charroux B, Martinez Vinson C et al. (2012). SKIV2L mutations cause syndromic diarrhea, or trichohepatoenteric syndrome. Am J Hum Genet. 90: 689-692. https://doi.org/10.1016/j.ajhg.2012.02.009; PMid:22444670 PMCid:PMC3322239

Fabre A, Martinez Vinson C, Roquelaure B et al. (2011). Novel mutations in TTC37 associated with tricho-hepato-enteric syndrome. Hum Mutat. 32: 277-281. https://doi.org/10.1002/humu.21420; PMid:21120949

Feagan BG, Chande N, MacDonald JK. (2013). Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from cochrane reviews. Inflamm Bowel Dis. 19: 2031-2040. https://doi.org/10.1097/MIB.0b013e3182920108; PMid:23811638

Fernandez I, Patey N, Marchand V et al. (2014). Multiple intestinal atresia with combined immune deficiency related to TTC7A defect is a multiorgan pathology: study of a French-Canadian-based cohort. Medicine (Baltimore). 93: e327. https://doi.org/10.1097/MD.0000000000000327; PMid:25546680 PMCid:PMC4602622

Ferry GD, Kirschner BS, Grand RJ et al. (1993). Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gastroenterol Nutr. 17: 32-38. https://doi.org/10.1097/00005176-199307000-00005; PMid:8102399

Fuentes D, Torrente F, Keady S et al. (2003). High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther. 17: 913-921. https://doi.org/10.1046/j.1365-2036.2003.01540.x; PMid:12656694

Glocker EO, Frede N, Perro M et al. (2010). Infant colitis - it's in the genes. Lancet. 376: 1272. https://doi.org/10.1016/S0140-6736(10)61008-2

Glocker EO, Kotlarz D, Boztug K et al. (2009). Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 361: 2033-2045. https://doi.org/10.1056/NEJMoa0907206; PMid:19890111 PMCid:PMC2787406

Green TJ, Issenman RM, Jacobson K. (1998). Patients' diets and preferences in a pediatric population with inflammatory bowel disease. Can J Gastroenterol. 12: 544-549. https://doi.org/10.1155/1998/928706; PMid:9926264

Hanai HIT, Takeuchi K et al. (2006). Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 4: 1502-1506. https://doi.org/10.1016/j.cgh.2006.08.008; PMid:17101300

Hata K, Watanabe T, Shinozaki M et al. (2003). Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol. 38: 1055-1058. https://doi.org/10.1080/00365520310005938; PMid:14621280

Henker J, Muller S, Laass MW et al. (2008). Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol. 46: 874-875. https://doi.org/10.1055/s-2008-1027463; PMid:18810672

Heyman MB, Kierkus J, Spenard J et al. (2010). Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. Inflamm Bowel Dis. 16: 1931-1939. https://doi.org/10.1002/ibd.21256; PMid:20848454 PMCid:PMC3252049

Huynh HQ, deBruyn J, Guan L et al. (2009). Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis. 15: 760-768. https://doi.org/10.1002/ibd.20816; PMid:19067432

Hyams J, Markowitz J, Lerer T et al. (2006). The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 4: 1118-1123. https://doi.org/10.1016/j.cgh.2006.04.008; PMid:16820327

Ikeda H, Ishimaru Y, Takayasu H et al. (2006). Efficacy of granulocyte apheresis in pediatric patients with ulcerative colitis: a pilot study. J Pediatr Gastroenterol Nutr. 43: 592-596. https://doi.org/10.1097/01.mpg.0000237928.07729.79; PMid:17130733

Jacobstein DA, Markowitz JE, Kirschner BS et al. (2005). Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis. 11: 442-446. https://doi.org/10.1097/01.MIB.0000158166.88238.ea; PMid:15867583

Jose FA, Garnett EA, Vittinghoff E et al. (2009). Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 15: 63-68. https://doi.org/10.1002/ibd.20604; PMid:18626963 PMCid:PMC2605161

Kader HA, Mascarenhas MR, Piccoli DA et al. (1999). Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr. 28: 54-58. https://doi.org/10.1097/00005176-199901000-00013; PMid:9890469

Kammermeier J, Dziubak R, Pescarin M et al. (2017). Phenotypic and genotypic characterisation of inflammatory bowel disease presenting before the age of 2 years. J Crohns Colitis. 11: 60-69. https://doi.org/10.1093/ecco-jcc/jjw118; PMid:27302973 PMCid:PMC5885808

Kellermayer R, Nagy Szakal D, Harris RA et al. (2015). Serial fecal microbiota transplantation alters mucosal gene expression in pediatric ulcerative colitis. Am J Gastroenterol. 110: 604-606. https://doi.org/10.1038/ajg.2015.19; PMid:25853207 PMCid:PMC4883582

Kennedy NA, Rhatigan E, Arnott ID et al. (2013). A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther. 38: 1255-1266. https://doi.org/10.1111/apt.12511; PMid:24117596

Khan KJ, Ullman TA, Ford AC et al. (2011). Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 106: 661-673. https://doi.org/10.1038/ajg.2011.72; PMid:21407187

Kirschner BS. (1998). Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology. 115: 813-821. https://doi.org/10.1016/S0016-5085(98)70251-3

Knod JL, Holder M, Cortez AR et al. (2016). Surgical outcomes, bowel habits and quality of life in young patients after ileoanal anastomosis for ulcerative colitis. J Pediatr Surg. 51: 1246-1250. https://doi.org/10.1016/j.jpedsurg.2016.03.002; PMid:27417342

Koivusalo A, Pakarinen MP, Rintala RJ. (2007). Surgical complications in relation to functional outcomes after ileoanal anastomosis in pediatric patients with ulcerative colitis. J Pediatr Surg. 42: 290-295. https://doi.org/10.1016/j.jpedsurg.2006.10.001; PMid:17270537

Koletzko S, Niggemann B, Arato A et al. (2012). Diagnostic approach and management of cow's-milk protein allergy in infants and children: ESPGHAN GI Committee practical guidelines. J Pediatr Gastroenterol Nutr. 55: 221-229. https://doi.org/10.1097/MPG.0b013e31825c9482; PMid:22569527

Kruis W, Fric P, Pokrotnieks J et al. (2004). Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 53: 1617-1623. https://doi.org/10.1136/gut.2003.037747; PMid:15479682 PMCid:PMC1774300

Kruis W, Schutz E, Fric P et al. (1997). Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 11: 853-858. https://doi.org/10.1046/j.1365-2036.1997.00225.x; PMid:9354192

Kunde S, Pham A, Bonczyk S et al. (2013). Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr. 56: 597-601. https://doi.org/10.1097/MPG.0b013e318292fa0d; PMid:23542823

Lahdenne P, Wikstrom AM, Aalto K et al. (2010). Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res (Hoboken). 62: 785-790. https://doi.org/10.1002/acr.20246; PMid:20535789

Lamet M. (2011). A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci. 56: 513-522. https://doi.org/10.1007/s10620-010-1334-y; PMid:20676771 PMCid:PMC3029674

Lang A, Salomon N, Wu JC et al. (2015). Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 13: 1444-1449. https://doi.org/10.1016/j.cgh.2015.02.019; PMid:25724700

Langhorst J, Wulfert H, Lauche R et al. (2015). Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohn Colitis. 9: 86-106. https://doi.org/10.1093/ecco-jcc/jju007; PMid:25518050

Langmead L, Feakins RM, Goldthorpe S et al. (2004). Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 19: 739-747. https://doi.org/10.1111/j.1365-2036.2004.01902.x; PMid:15043514

Lawrance IC, Baird A, Lightower D et al. (2017). Efficacy of rectal tacrolimus for induction therapy in patients with resistant ulcerative proctitis. Clin Gastroenterol Hepatol. 15: 1248-1255. https://doi.org/10.1016/j.cgh.2017.02.027; PMid:28286194

Lawrance IC, Copeland TS. (2008). Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther. 28: 1214-1220. https://doi.org/10.1111/j.1365-2036.2008.03841.x; PMid:18761706

Lee CH, Tasker N, La Hei E et al. (2014). Raised tacrolimus level and acute renal injury associated with acute gastroenteritis in a child receiving local rectal tacrolimus. Clin J Gastroenterol. 7: 238-242. https://doi.org/10.1007/s12328-014-0482-6; PMid:26183743

Lemoine R, Pachlopnik Schmid J, Farin HF et al. (2014). Immune deficiency-related enteropathy-lymphocytopenia-alopecia syndrome results from tetratricopeptide repeat domain 7A deficiency. J Allergy Clin Immunol. 134: 1354-1364. https://doi.org/10.1016/j.jaci.2014.07.019; PMid:25174867

Lewis JD, Abreu MT. (2017). Diet as a trigger or therapy for inflammatory bowel diseases. Gastroenterology. 152: 398-414. https://doi.org/10.1053/j.gastro.2016.10.019; PMid:27793606

Lipman JM, Kiran RP, Shen B et al. (2011). Perioperative factors during ileal pouch-anal anastomosis predict pouchitis. Dis Colon Rectum. 54: 311-317. https://doi.org/10.1007/DCR.0b013e3181fded4d; PMid:21304302

Marshall JK, Thabane M, Steinhart AH et al. (2010). Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 1: CD004115. https://doi.org/10.1002/14651858.CD004115.pub2; PMid:20091560

Marshall JK, Thabane M, Steinhart AH et al. (2012). Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 11: CD004118. https://doi.org/10.1002/14651858.CD004118.pub2; PMid:23152224

Marteau P, Probert CS, Lindgren S et al. (2005). Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 54: 960-965. https://doi.org/10.1136/gut.2004.060103; PMid:15951542 PMCid:PMC1774619

Martin de Carpi J, Vilar P, Prieto G et al. (2008). Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study. J Pediatr Gastroenterol Nutr. 46: 386-391. https://doi.org/10.1097/MPG.0b013e31815604e5; PMid:18367949

Meier CB, Hegazi RA, Aisenberg J et al. (2005). Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? Inflamm Bowel Dis. 11: 965-971. https://doi.org/10.1097/01.MIB.0000186407.25694.cf; PMid:16239841

Merkley SA, Beaulieu DB, Horst S et al. (2015). Use of intravenous immunoglobulin for patients with inflammatory bowel disease with contraindications or who are unresponsive to conventional treatments. Inflamm Bowel Dis. 21: 1854-1859. https://doi.org/10.1097/MIB.0000000000000456; PMid:25993689

Merrett MN, Mortensen N, Kettlewell M et al. (1996). Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. Gut. 38: 362-364. https://doi.org/10.1136/gut.38.3.362; PMid:8675087 PMCid:PMC1383063

Miele E, Shamir R, Aloi M et al. (2018). Nutrition in paediatric inflammatory bowel disease: a position paper on behalf of The Porto IBD Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 66: 687-708. https://doi.org/10.1097/MPG.0000000000001896; PMid:29570147

Moes N, Rieux Laucat F, Begue B et al. (2010). Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy. Gastroenterology. 139: 770-778. https://doi.org/10.1053/j.gastro.2010.06.006; PMid:20537998

Naidoo K, Gordon M, Fagbemi AO et al. (2011). Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 12: CD007443. https://doi.org/10.1002/14651858.CD007443.pub2; PMid:22161412

Nanau RM, Cohen LE, Neuman MG. (2014). Risk of infections of biological therapies with accent on inflammatory bowel disease. J Pharm Pharm Sci. 17: 485-531. https://doi.org/10.18433/J3GG6D; PMid:25579431

Ng SC, Lam YT, Tsoi KK et al. (2013). Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 38: 854-863. https://doi.org/10.1111/apt.12464; PMid:23981095

Nikfar S, Rahimi R, Rezaie A et al. (2009). A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci. 54: 1157-1170. https://doi.org/10.1007/s10620-008-0481-x; PMid:18770034

Okhotnikova OM, Tkacheva TM, Romanchuk AA, Grishchenko OM, Voronyak DS. (2019). Modern algorithm for the diagnosis of ulcerative colitis in children according to the latest recommendations of the European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. Modern Pediatrics. Ukraine. 7(103): 33-43. https://doi.org/10.15574/SP.2019.103.33

Oliva Hemker M, Hutfless S, Al Kazzi ES et al. (2015). Clinical presentation and five-year therapeutic management of very early-onset inflammatory bowel disease in a large North American cohort. J Pediatr. 167: 527-532. https://doi.org/10.1016/j.jpeds.2015.04.045; PMid:25982142

Orlanski Meyer E, Topf Olivestone C, Ledder O et al. (2017). Pouchitis in paediatric UC: a multicentre longitudinal cohort study from the Porto IBD working group of ESPGHAN. ESPGHAN Annual Meeting, Prague; Abstr G-O-038. https://doi.org/10.1093/ecco-jcc/jjx002.284

Ozdemir Y, Kiran RP, Erem HH et al. (2014). Functional outcomes and complications after restorative proctocolectomy and ileal pouch anal anastomosis in the pediatric population. J Am Coll Surg. 218: 328-335. https://doi.org/10.1016/j.jamcollsurg.2013.11.019; PMid:24468224

Pachlopnik Schmid J, Canioni D, Moshous D et al. (2011). Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 117: 1522-1529. https://doi.org/10.1182/blood-2010-07-298372; PMid:21119115

Pakarinen MP, Natunen J, Ashorn M et al. (2009). Long-term outcomes of restorative proctocolectomy in children with ulcerative colitis. Pediatrics. 123: 1377-1382. https://doi.org/10.1542/peds.2008-2086; PMid:19403505

Patton D, Gupta N, Wojcicki JM et al. (2010). Postoperative outcome of colectomy for pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr. 51: 151-154. https://doi.org/10.1097/MPG.0b013e3181c99290; PMid:20410838 PMCid:PMC3119923

Polites SF, Potter DD, Moir CR et al. (2015). Long-term outcomes of ileal pouch-anal anastomosis for pediatric chronic ulcerative colitis. J Pediatr Surg. 50: 1625-1629. https://doi.org/10.1016/j.jpedsurg.2015.03.044; PMid:25863545

Pozler O, Chladek J, Maly J et al. (2010). Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. J Crohns Colitis. 4: 623-628. https://doi.org/10.1016/j.crohns.2010.06.005; PMid:21122571

Prenzel F, Uhlig HH. (2009). Frequency of indeterminate colitis in children and adults with IBD-a metaanalysis. J Crohns Colitis. 3: 277-281. https://doi.org/10.1016/j.crohns.2009.07.001; PMid:21172287

Probert CS, Dignass AU, Lindgren S et al. (2014). Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis. 8: 200-207. https://doi.org/10.1016/j.crohns.2013.08.007; PMid:24012063

Rembacken BJ, Snelling AM, Hawkey PM et al. (1999). Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 354: 635-639. https://doi.org/10.1016/S0140-6736(98)06343-0

Ruuska T, Wewer V, Lindgren F et al. (2009). Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: results, practical issues, safety, and future perspectives. Inflamm Bowel Dis. 15: 1049-1054. https://doi.org/10.1002/ibd.20859; PMid:19137602

Sandborn WJ, Landers CJ, Tremaine WJ et al. (1995). Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouchanal anastomosis. Am J Gastroenterol. 90: 740-747.

Sandborn WJ. (1996). A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 91: 423-433.

Seetharamaiah R, West BT, Ignash SJ et al. (2009). Outcomes in pediatric patients undergoing straight vs J pouch ileoanal anastomosis: a multicenter analysis. J Pediatr Surg. 44: 1410-1417. https://doi.org/10.1016/j.jpedsurg.2009.01.006; PMid:19573671

Shannon A, Eng K, Kay M et al. (2016). Long-term follow up of ileal pouch anal anastomosis in a large cohort of pediatric and young adult patients with ulcerative colitis. J Pediatr Surg. 51: 1181-1186. https://doi.org/10.1016/j.jpedsurg.2015.12.012; PMid:26876089

Suskind DL, Singh N, Nielson H et al. (2015). Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 60: 27-29. https://doi.org/10.1097/MPG.0000000000000544; PMid:25162366

Suskind DL, Wahbeh G, Burpee T et al. (2013). Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. J Pediatr Gastroenterol Nutr. 56: 277-279. https://doi.org/10.1097/MPG.0b013e318276977d; PMid:23059643 PMCid:PMC3701433

Tajiri H, Tomomasa T, Yoden A et al. (2008). Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease. Digestion. 77: 150-154. https://doi.org/10.1159/000140974; PMid:18577852

Tanaka T, Okanobu H, Kuga Y et al. (2010). Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol. 34: 687-695. https://doi.org/10.1016/j.gcb.2010.08.007; PMid:20934287

Tomomasa T, Kobayashi A, Kaneko H et al. (2003). Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig Dis Sci. 48: 750-754.

Tomomasa T, Tajiri H, Kagimoto S et al. (2011). Leukocytapheresis in pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr. 53: 34-39. https://doi.org/10.1097/MPG.0b013e31821058bc; PMid:21694533

Torgerson TR, Linane A, Moes N et al. (2007). Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene. Gastroenterology. 132: 1705-1717. https://doi.org/10.1053/j.gastro.2007.02.044; PMid:17484868

Tung J, Loftus EV Jr, Freese DK et al. (2006). A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 12: 1093-1100. https://doi.org/10.1097/01.mib.0000235835.32176.85; PMid:17119382

Turner D, Yerushalmi B, Kori M et al. (2017). Once-versus twice-daily mesalazine to induce remission in paediatric ulcerative colitis: a randomised controlled trial. J Crohns Colitis. 11: 527-533. https://doi.org/10.1093/ecco-jcc/jjw180; PMid:28453754

Tyler AD, Milgrom R, Xu W et al. (2012). Antimicrobial antibodies are associated with a Crohn's disease-like phenotype after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 10: 507-512. https://doi.org/10.1016/j.cgh.2011.09.016; PMid:21963956

Uhlig HH, Schwerd T, Koletzko S et al. (2014). The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 147: 990-1007. https://doi.org/10.1053/j.gastro.2014.07.023; PMid:25058236 PMCid:PMC5376484

Van Limbergen J, Russell RK, Drummond HE et al. (2008). Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 135: 1114-1122. https://doi.org/10.1053/j.gastro.2008.06.081; PMid:18725221

Verhave M, Winter HS, Grand RJ. (1990). Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr. 117: 809-814. https://doi.org/10.1016/S0022-3476(05)83349-9

Wang SL, Wang ZR, Yang CQ. (2012). Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med. 4: 1051-1056. https://doi.org/10.3892/etm.2012.718; PMid:23226773 PMCid:PMC3494118

Watanabe M, Nishino H, Sameshima Y et al. (2013). Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - a placebo-controlled study. Aliment Pharmacol Ther. 38: 264-273. https://doi.org/10.1111/apt.12362; PMid:23734840

Wildin RS, Ramsdell F, Peake J et al. (2001). X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 27: 18-20. https://doi.org/10.1038/83707; PMid:11137992

Winter HS, Krzeski P, Heyman MB et al. (2014). High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis. J Pediatr Gastroenterol Nutr. 59: 767-772. https://doi.org/10.1097/MPG.0000000000000530; PMid:25419597 PMCid:PMC4255757

Wu XR, Ashburn J, Remzi FH et al. (2016). Male gender is associated with a high risk for chronic antibiotic-refractory pouchitis and ileal pouch anastomotic sinus. J Gastrointest Surg. 20: 631-639. https://doi.org/10.1007/s11605-015-2976-z; PMid:26446071

Downloads

Published

2021-03-27

Issue

No. 2(114) (2021): Modern pediatrics. Ukraine

Section

Reviews

License

Copyright (c) 2021 Modern Pediatrics. Ukraine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a  Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).

Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.

Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.

The use of published materials for commercial purposes is strongly prohibited.